Production (Stage)
Ovid Therapeutics Inc.
OVID
$0.3186
$0.00531.69%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 71.05% | -56.07% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 71.05% | -56.07% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 71.05% | -56.07% | |||
| SG&A Expenses | -11.13% | 22.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.29% | -17.92% | |||
| Operating Income | -14.91% | 17.42% | |||
| Income Before Tax | -10.61% | 33.94% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -10.61% | 33.94% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -10.61% | 33.94% | |||
| EBIT | -14.91% | 17.42% | |||
| EBITDA | -15.30% | 17.58% | |||
| EPS Basic | -14.29% | 37.20% | |||
| Normalized Basic EPS | -29.30% | 33.58% | |||
| EPS Diluted | -12.11% | 36.85% | |||
| Normalized Diluted EPS | -29.30% | 33.58% | |||
| Average Basic Shares Outstanding | 0.05% | 0.05% | |||
| Average Diluted Shares Outstanding | 0.05% | 0.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||